.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Express Scripts
Harvard Business School
Merck
US Army
US Department of Justice
Fuji
Fish and Richardson
Dow
McKinsey

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,455,540

« Back to Dashboard

Which drugs does patent 6,455,540 protect, and when does it expire?


Patent 6,455,540 protects FACTIVE and is included in one NDA. There has been one Paragraph IV challenge on Factive.

This patent has thirteen patent family members in twelve countries.

Summary for Patent: 6,455,540

Title: Methods of use of quinolone compounds against anaerobic pathogenic bacteria
Abstract:This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against pathogenic bacteria, especially anaerobic pathogens.
Inventor(s): Citron; Diane M. (Santa Monica, CA), Goldstein; Ellie J. C. (Santa Monica, CA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:09/976,323
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Lg Chem Ltd
FACTIVE
gemifloxacin mesylate
TABLET;ORAL021158-001Apr 4, 2003ABRXYesYes► Subscribe► Subscribe USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,455,540

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,938,154 System, method and article of manufacture for a cryptographic key infrastructure for networked devices► Subscribe
6,262,071 Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria► Subscribe
6,340,689 Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria► Subscribe
6,803,376 Method of use of quinolone compounds against pneumococcal and haemophilus bacteria► Subscribe
6,331,550 Methods of use of quinolone compounds against anaerobic pathogenic bacteria► Subscribe
7,595,328Methods of use of quinolone compounds against pneumococcal and Haemophilus bacteria► Subscribe
6,279,257 Flush mounting security frames and hardware► Subscribe
6,659,418 Positioning & locking hanging system► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,455,540

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria383157► Subscribe
Australia6201600► Subscribe
Canada2281817► Subscribe
Canada2282066► Subscribe
Canada2283141► Subscribe
Canada2283352► Subscribe
Cyprus1107381► Subscribe
Germany60037741► Subscribe
Denmark1223935► Subscribe
European Patent Office1223935► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Dow
Cantor Fitzgerald
Fish and Richardson
QuintilesIMS
Accenture
UBS
Cerilliant
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot